TARGET-NASH队列中MASLD患者多重用药的规模及疾病严重程度和患者性别与用药的关系
研究利用TARGET-NASH真实世界纵向观察队列,评估5190名美国成人MASLD患者的多重用药情况。结果显示90%患者被处方5种及以上药物,75%被处方10种及以上药物(其中63%为女性);肝硬化患者常被处方非甾体抗炎药(64%)、阿片类(55%)或苯二氮䓬类(45%)。女性用药多于男性,尤其在选择性5-羟色胺再摄取抑制剂、阿片类、质子泵抑制剂和苯二氮䓬类方面。
要点
- MASLD患者中多重用药普遍,90%被处方≥5种药物,75%被处方≥10种药物。
- 肝硬化患者常被处方非甾体抗炎药(64%)、阿片类(55%)或苯二氮䓬类(45%)。
- 女性比男性被处方更多药物,包括选择性5-羟色胺再摄取抑制剂(37% vs. 20%)。
核心结论
- MASLD患者中多重用药普遍,肝硬化患者受影响最大,女性肝硬化患者风险更高。
- 尽管存在已知风险,阿片类、苯二氮䓬类和非甾体抗炎药在肝硬化患者中仍普遍使用。
- 肝硬化患者频繁使用慢性疼痛药物,凸显需要平衡安全性与疗效的管理计划。
研究设计与样本
- 研究利用TARGET-NASH真实世界纵向观察队列中成人MASLD患者的数据。
- 共评估5190名美国成人(59%为女性),涵盖MASLD全谱。
- 计数报告的药物,描述其与疾病严重程度、性别和保险的关系,使用卡方或Fisher精确检验识别显著差异。
主要发现
- 90%患者被处方5种及以上药物,75%被处方10种及以上药物(其中63%为女性)。
- 肝硬化患者常被处方非甾体抗炎药(64%)、阿片类(55%)或苯二氮䓬类(45%)。
- 女性比男性被处方更多药物,特别是选择性5-羟色胺再摄取抑制剂(37% vs. 20%)、阿片类(44% vs. 37%)、质子泵抑制剂(63% vs. 52%)和苯二氮䓬类(41% vs. 31%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is common among patients with multiple comorbidities but may compromise patient health due to medication interactions, cumulative side effects and compliance challenges. AIM: Characterise the extent of polypharmacy and assess the effects of sex, liver disease severity and comorbidities in patients with metabolic dysfunction associated steatotic liver disease (MASLD) in a real-world setting. METHODS: Data from adults enrolled in TARGET-NASH, a real-world longitudinal observational cohort of patients with MASLD, were utilised. Reported medications were counted and relationships to disease severity, sex and insurance are described. Significant differences were identified using Chi-square or Fisher's exact test. RESULTS: Medication use was evaluated in 5190 adults (59% female) in the United States with the full spectrum of MASLD revealing that 90% were prescribed five or more medications and 75% were prescribed ten or more medications (63% of whom were females). Patients with cirrhosis were often prescribed nonsteroidal anti-inflammatory drugs (64%), opioids (55%), or benzodiazepines (45%). Females were prescribed more medications than males, particularly selective serotonin reuptake inhibitors (37% vs. 20%), opioids (44% vs. 37%), proton pump inhibitors (63% vs. 52%) and benzodiazepines (41% vs. 31%). CONCLUSIONS: Polypharmacy is common among patients with MASLD. Those with cirrhosis are most affected, and women with cirrhosis are at an even greater risk. Opioid, benzodiazepine, and nonsteroidal anti-inflammatory drug use is prevalent among patients with cirrhosis despite the known associated risks. Frequent medication use for chronic pain in patients with cirrhosis highlights the need for management plans that optimise safety balanced against therapeutic efficacy.
引用
- Neuschwander-Tetri BA, Morris HL, Mospan AR, et al. The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH. Aliment Pharmacol Ther. 2025. PMID: 40665787. doi:10.1111/apt.70278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。